WASHINGTON--Samuel Broder, MD, head of the National Cancer Institute (NCI) for the past 5 years, says that he will resign his post in April of this year. He will join IVAX Corporation (Miami), a manufacturer of generic drugs and IV drug delivery devices, where he plans to work on developing new drugs.

Dr. Broder first joined the NCI in 1972 as a researcher. He was the leader of a group that discovered the therapeutic benefits of the antiretroviral agent zidovudine (Retrovir, AZT) in 1985.